GH Research PLC (Nasdaq: GHRS) has launched an underwritten public offering in the United States of $150 million of ordinary shares. The company said in its offering document that it intends to use the net proceeds to strategically invest in research, clinical, and technical development of current and/or additional product candidates, working…
Please login to read all 464 words.
